Charbel Fadel | Pharmacology | Best Researcher Award

Charbel Fadel | Pharmacology | Best Researcher Award

Dr. Charbel Fadel, University of Pisa, Italy

Dr. Charbel Fadel is a renowned researcher in Veterinary Pharmacology with a PhD from the University of Sassari, Italy. He specializes in pharmacotherapy, quality control, and pharmacokinetics. Currently, Dr. Fadel is a Research Fellow at the University of Pisa, Italy, overseeing pharmacology lab operations and conducting animal studies. With a rich background in veterinary medicine, he has contributed to numerous scientific publications and presented at prestigious international conferences. Dr. Fadel’s work is focused on drug disposition, antimicrobial resistance, and improving veterinary pharmacology practices globally. He holds multiple honors and continues to impact veterinary science.

Publication Profile

Scopus

Education

Dr. Charbel Fadel is a distinguished veterinarian with extensive academic qualifications. He earned his Ph.D. in Veterinary Pharmacology, Pharmacotherapy, and Quality Control from the University of Sassari, Italy, in October 2023. Prior to this, he completed a Master’s degree in Veterinary Medicine, specializing in Small Animals’ Medicine, at L’Université Libanaise, Lebanon, in October 2020. His expertise in veterinary pharmacology and small animal care, combined with a passion for enhancing animal health, defines his professional journey.

Experience

Dr. Charbel Fadel has a rich professional background in veterinary medicine. Currently, he serves as a Research Fellow in Veterinary Pharmacology at the University of Pisa, Italy, where he oversees lab operations, manages pharmacokinetic studies, and collaborates with international teams to refine pharmacotherapy strategies. Before this, he was the Project and Operations Manager at IVet Medical in Beirut, Lebanon. In this role, he provided expert guidance to veterinarians on the use of biomedical machines, biological tests, and surgical instruments, while also managing the procurement and evaluation of medical supplies.

Awards

Dr. Charbel Fadel has earned numerous honors throughout his career. He has been an active reviewer for the Journal of Veterinary Pharmacology and Therapeutics since 2023 and was awarded the “Cultore della Materia” honor by the University of Pisa in January 2024 for his work as a Subject Specialist/Adjunct Lecturer. He received second runner-up for the 2023 JVPT Paper Award from Wiley Publishers, and his article on robenacoxib pharmacokinetics was recognized as the most cited in 2022-2023. Dr. Fadel also contributed to the “Rocinate Program” and completed several veterinary training programs in Russia.

Research Focus

Dr. Charbel Fadel’s research focus lies in veterinary pharmacology, particularly in the comparative pharmacokinetics of various drugs in livestock species like sheep and goats. His studies, including those on metronidazole and omeprazole, aim to enhance the understanding of drug absorption, distribution, metabolism, and excretion in these animals. This research is crucial for optimizing veterinary care and ensuring effective medication dosages in different animal species. Dr. Fadel’s work supports the development of more tailored and efficient treatment protocols for livestock, contributing to both animal health and agricultural practices.

Publication Top Notes

Comparative pharmacokinetic evaluation of metronidazole in sheep and goats

Comparative Pharmacokinetics of Intravenous and Subcutaneous Omeprazole in Sheep and Goats

yang huanzhi | Pharmacology | Best Researcher Award

yang huanzhi | Pharmacology | Best Researcher Award

Dr. yang huanzhi, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, China, China

Dr. Huanzhi Yang is a Ph.D. candidate in Food Science and Engineering at China Agricultural University (2019–2025) 🎓, focusing on food nutrition, natural products, and chronic disease prevention. With a strong academic background from Hunan Agricultural University and Huaihua University, his research spans functional food development, gut health, and antioxidants. He has authored multiple high-impact publications 📝, holds several international patents 🧪, and has collaborated on national food science projects. Recognized for his innovation and excellence, Dr. Yang has received numerous scholarships, awards, and honors 🏆, showcasing his commitment to scientific advancement and food health solutions.

Publication Profile

Scopus

Education

Dr. Yang Huanzhi 🎓 is currently pursuing a Ph.D. in Engineering at China Agricultural University (2019.09–2025.06), specializing in Food Science and Engineering under the guidance of Prof. Xiaojun Liao 🍎. He earned his Master’s degree in Bioengineering from Hunan Agricultural University (2016.09–2018.06), mentored by Prof. Guoping Peng 🧬. Dr. Yang began his academic journey at Huaihua University, where he completed his Bachelor’s degree in Bioengineering (2012.09–2016.06) 📘. With a solid foundation in food and biosciences, his research focuses on advancing food science and nutritional engineering for a healthier future 🌱.

Experience

Dr. Yang Huanzhi’s research focuses on food nutrition and health 🍽️, emphasizing the role of natural products in preventing and controlling chronic diseases 💊. With a passion for improving public well-being, he explores the bioactive components in natural sources 🌿 and their potential in promoting long-term health. His work contributes to the development of functional foods that not only nourish but also serve therapeutic purposes 🥦. By integrating nutritional science with innovative food engineering, Dr. Yang aims to create sustainable, health-promoting dietary solutions for modern lifestyles 🧠❤️. His dedication is shaping the future of preventive nutrition and wellness.

Awards

Dr. Yang Huanzhi has been recognized for his outstanding academic and research achievements 🌟. From 2020 to 2024, he consistently received the “Second Class Scholarship” 🏅 for five consecutive years during his doctoral studies at China Agricultural University. In 2022, he earned the second prize in the 3rd “Xingnong Cup” Innovation and Entrepreneurship Competition 💡. His dedication to safety and responsibility earned him the honorary title of Excellent Laboratory Safety Officer for two consecutive years (2021–2022) 🧪🛡️. Additionally, in 2019, his master’s work was honored with the “Excellent Master’s Thesis” award from Hunan Agricultural University 📜🏆.

Research Focus

Dr. Yang Huanzhi focuses on nutraceuticals, gut microbiota, and inflammation-related diseases. His research delves into how natural plant-based compounds—particularly polyphenols from CiLi (Rosa roxburghii Tratt.)—can modulate the gut microbiota-lipid mediator-immunity axis to alleviate chronic inflammatory conditions such as colitis. 🌿 His work bridges phytochemistry, immunology, and microbiome research, emphasizing the therapeutic potential of functional foods and dietary interventions. 🧫💊 By uncovering the molecular pathways through which CiLi polyphenols influence gut health and immune regulation, Dr. Huanzhi contributes to the advancement of integrative medicine and functional nutrition in disease prevention and treatment.

Publication Top Notes

CiLi (Rosa roxburghii Tratt.) polyphenols improve colitis via gut microbiota-lipid mediator-immunity axis

Prof Dr. Elaine Leung|Pharmacology | Best Researcher Award

Prof Dr. Elaine Leung |Pharmacology|Best Researcher Award|

Prof Dr. Elaine Leung at Department of Biomedical Science, Faculty of Health Science, Macau

PROFILE  

scopus

 

Early Academic Pursuits 🎓

Elaine Lai-Han Leung embarked on her academic journey with a strong foundation in biological sciences, obtaining her BSc in Biology and Biochemistry from The Chinese University of Hong Kong in 2001. Her deep interest in biomedical sciences led her to pursue further studies, earning an MPhil in Biochemistry in 2003, followed by a PhD in Physiology in 2006 from the same institution. Her early academic pursuits laid the groundwork for a career marked by significant contributions to biomedical research, particularly in the fields of cancer biology and traditional Chinese medicine.

Professional Endeavors 🧬

Professor Leung’s professional career has been centered at the University of Macau, where she is a prominent figure in the Department of Biomedical Science, Faculty of Health Science. Over the years, she has established herself as a leading researcher, focusing on the intersection of modern biomedical sciences and traditional Chinese medicine. Her work has involved both academic research and collaborations with industry, where she has taken on numerous consultancy projects, contributing to the development of new therapies and drug discoveries.

Contributions and Research Focus 🔬

Professor Leung’s research is primarily focused on cancer biology, with an emphasis on non-small cell lung cancer (NSCLC). She has been the principal investigator (PI) or co-investigator (Co-I) on numerous research projects, many of which are aimed at understanding the mechanisms of drug resistance and the development of novel therapeutic strategies. Her ongoing research includes studies on KRAS resistance mechanisms, the role of gut microbiota in cancer immunomodulation, and the use of traditional Chinese medicine in treating various forms of cancer.

Some of her key projects include:

  • The relationship between KRAS resistance mechanisms and the immune microenvironment: An ongoing project at the University of Macau aimed at uncovering how KRAS mutations affect immune responses in cancer.
  • High-dimensional single-cell analysis of Sotorasib resistance clinical samples: This research seeks to identify new small molecule inhibitors for treating NSCLC.
  • Investigation of the anti-tumor effect of microbial valeric acid in NSCLC: Completed in 2023, this study explored how microbial byproducts can influence tumor immunity.

Accolades and Recognition 🏆

Professor Leung’s contributions to biomedical science have not gone unnoticed. She has been recognized with numerous awards and honors throughout her career, reflecting her standing in the scientific community. Her work has been cited extensively in leading scientific journals, with her citation index reflecting her influence in the fields of cancer biology and traditional Chinese medicine. Her collaboration with Nobel Laureate Erwin Neher on drug research further underscores her prominence in the field.

Impact and Influence 🌍

The impact of Professor Leung’s work extends beyond academia. Her research has significant implications for the development of new cancer therapies, particularly in the context of drug resistance. By bridging the gap between traditional Chinese medicine and modern biomedical research, she has opened new avenues for treatment that could benefit patients worldwide. Her work on gut microbiota and its role in cancer treatment, for instance, is pioneering in its approach and has the potential to revolutionize how cancer is treated.

Legacy and Future Contributions 🌟

As Professor Leung continues her work at the University of Macau, her legacy is already taking shape. She is helping to mentor the next generation of scientists while pushing the boundaries of what is possible in cancer research. Her ongoing projects, including those funded by significant grants, are expected to yield new insights into cancer biology and treatment. Looking ahead, her contributions will likely continue to influence the field of biomedical sciences, particularly in how traditional Chinese medicine is integrated into modern therapeutic strategies.

Research and Innovations 🧪

Completed/Ongoing Research Projects 📊

Professor Leung has completed numerous research projects, with many others ongoing. Her portfolio includes more than a dozen major projects, ranging from small-scale studies to large, collaborative efforts with industry partners. These projects have attracted significant funding, including:

  • Macao Science and Technology Development Fund (2021/2024): Investigating the combinational treatment effects of ginseng polysaccharides with immunotherapy in lung cancer, with a budget of USD 230,769.
  • Zhuhai UM Science and Technology Institute joint lab projects: Ongoing studies on drug resistance and immune microenvironment interactions in cancer, funded at approximately USD 641,000.

Citation Index 📚

Professor Leung’s work is highly regarded in the scientific community, as reflected by her citation index in databases such as Scopus and the Science Citation Index (SCI). Her research articles have been cited extensively, demonstrating the impact and relevance of her work in advancing biomedical science.

Consultancy/Industry Projects 🤝

Beyond academia, Professor Leung has engaged in several industry-sponsored projects, often serving as a consultant. These projects have allowed her to apply her research in practical settings, contributing to the development of new drugs and therapeutic strategies. Notably, she has collaborated with leading pharmaceutical companies like Janssen Pharmaceuticals, where her work on immunophenotyping in lung cancer patients has been highly influential.

Conclusion 🎯

Professor Elaine Lai-Han Leung’s career is a testament to the power of interdisciplinary research and collaboration. Her contributions to cancer biology, her innovative use of traditional Chinese medicine, and her commitment to bridging the gap between research and industry have made her a pivotal figure in her field. As she continues to explore new frontiers in biomedical science, her legacy will undoubtedly be one of lasting impact, shaping the future of cancer treatment and beyond.

🎓Publication 

Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer

  • Authors   :Zhang, Y.-Z., Lai, H.-L., Huang, C., Wu, Q.-B., Leung, E.L.-H.
  • Journal    :Phytomedicine
  • Year         :2024

Genome engineering of the human gut microbiome

MMP14high macrophages orchestrate progressive pulmonary fibrosis in SR-Ag-induced hypersensitivity pneumonitis

  • Authors   :Peng, D., Li, J., Li, Y., Yang, P., Li, G.
  • Journal    :Pharmacological Research.
  • Year         :2024

Paris saponin VII reverses resistance to PARP inhibitors by regulating ovarian cancer tumor angiogenesis and glycolysis through the RORα/ECM1/VEGFR2 signaling axis